Differences in skeletal muscle loss caused by cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non‐small cell lung cancer

BACKGROUND: Recent studies have revealed a reduction in the skeletal muscle area in patients with advanced non‐small cell lung cancer (NSCLC) after chemotherapy. EGFR and ALK tyrosine kinase inhibitor (TKI)‐based therapies are less cytotoxic than chemotherapy, but differences in skeletal muscle mass...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Thorac Cancer
Hoofdauteurs: Kakinuma, Kazutaka, Tsuruoka, Hazime, Morikawa, Kei, Furuya, Naoki, Inoue, Takeo, Miyazawa, Teruomi, Mineshita, Masamichi
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley & Sons Australia, Ltd 2017
Onderwerpen:
Original Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5754304/
https://ncbi.nlm.nih.gov/pubmed/29067769
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12545
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items